Company news
Jyong Biotech Ltd. (NASDAQ:MENS) news
Jyong Biotech Ltd. news releases on 6ix. Latest, Sep 3, 2026: Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow
Press releases & updates
Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow
September 3, 2026
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
July 23, 2026
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention
July 2, 2026
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
May 28, 2026
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
May 15, 2026
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio
April 28, 2026
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
March 26, 2026
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia
February 12, 2026
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
January 30, 2026
Jyong Biotech Responds to Share Price and Volume Movement
December 18, 2025
Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry
December 3, 2025
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs
November 23, 2025
Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes
November 19, 2025
Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards
September 28, 2025
Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei
September 17, 2025
Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention
September 15, 2025
Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)
August 21, 2025
Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention
July 22, 2025
Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention
July 21, 2025
Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering
June 17, 2025